Group 1: Financial Performance - The company achieved a revenue of 270,833.74 million CNY in the first half of 2025, representing a 4.16% increase compared to the same period last year [1] - The net profit attributable to shareholders was 893,533.16 CNY, showing a decline compared to the previous year [1] Group 2: Strategic Focus - The company is transitioning from traditional business growth models to a focus on innovation, high-quality, and diversified operations [1] - Emphasis on developing products and technologies in the field of regenerative medicine to enhance research innovation and clinical transformation [2] Group 3: Cost Management and Profitability - The company aims to strengthen cost control to reduce expenses in production, operations, and management, thereby improving profit margins [2] - The goal is to stabilize company performance and enhance profitability [2] Group 4: Investment Value and Market Position - The company is committed to solidifying its core competitiveness and profitability through talent development and leveraging existing business [2] - The company is poised to capitalize on opportunities in the healthcare industry to enhance its market position and service quality [2] Group 5: Regulatory Environment - Recent government policies promoting consumption and easing market access for high-end medical services are seen as positive signals for the company [2] - The company will closely monitor market demand and actively apply for relevant licenses in response to the new policy environment [2]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-062 湖南达嘉维康医药产业股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）为满足公司全资 子公司及控股子公司日常生产经营和业务发展资金需要，保证公司业务顺利开展， 公司于 2025 年 4 月 17 日、2025 年 5 月 12 日分别召开的第四届董事会第十四次会 议及 2024 年年度股东大会审议通过《关于 2025 年度担保额度预计的议案》，同意 公司 2025 年度为公司全资子公司及控股子公司提供担保，担保额度预计不超过 30 亿 元。具体内容详见公司于 2025 年 4 月 21 日在巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于 2025 年度担保额度预计的公告》（公告编号：2025-026）。 二、对外担保进展情况 近日，公司与中国民生银行股份有限公司长沙分行（以下简称"民生银行"） 签订了《最高额保证合同》，同意为全资子公司湖南达嘉维康医药有 ...

Group 1 - On September 15, Dajia Weikang's stock price fell by 0.59%, with a trading volume of 27.33 million yuan [1] - The financing data on the same day showed a financing purchase amount of 2.91 million yuan and a financing repayment of 4.03 million yuan, resulting in a net financing outflow of 1.13 million yuan [1] - As of September 15, the total balance of margin trading for Dajia Weikang was 88.47 million yuan, accounting for 3.62% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of September 10, the number of shareholders for Dajia Weikang was 16,500, an increase of 0.40% from the previous period, while the average circulating shares per person decreased by 0.39% to 8,378 shares [2] - For the first half of 2025, Dajia Weikang achieved an operating income of 2.708 billion yuan, a year-on-year increase of 4.16%, but the net profit attributable to the parent company was only 893,500 yuan, a significant decrease of 97.19% year-on-year [2] Group 3 - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders included the newly entered Noan Multi-Strategy Mixed A fund, holding 939,800 shares [3]

Group 1 - The company, Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd., will participate in the 2025 Hunan Listed Companies Investor Online Collective Reception Day and Semi-Annual Performance Briefing [1][2] - The event will be held online on September 19, 2025, from 14:00 to 17:00, allowing investors to engage through the "Panjing Roadshow" website or its associated platforms [1][2] - Company executives will discuss key topics including the company's performance for the first half of 2024 to 2025, governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-061 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:00-17:00。 届时公司高管将在线就公司 2024 年至 2025 半年度业绩、公司治理、发展 战略、经营状况、融资计划、股权激励和可持续发展等投资者关心的问题，与 投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 湖南达嘉维康医药产业股份有限公司董事会 2025 年 9 月 12 日 湖南达嘉维康医药产业股份有限公司 关于参加 2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，湖南达嘉维康医药产业股份有限公司 （以下简称"公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全 景网络有限公司联合举办的"资本聚三湘 楚光耀新程——20 ...

Group 1 - The core point of the article is that Dajia Weikang (301126) reported on September 12 that as of September 10, 2025, the number of shareholders reached 16,456 [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

Group 1 - The company has opened multiple 24-hour unmanned pharmacies to enhance operational efficiency and service quality through technology [1] - The initiative aims to provide customers with a more convenient medication purchasing experience [1]

Core Viewpoint - Li Yulan plans to reduce her holdings in Dajia Weikang through centralized bidding from June 6, 2025, to September 5, 2025, by no more than 50,000 shares, accounting for 0.024% of total shares [1] Summary by Relevant Sections - **Share Reduction Details** - On June 6, July 30, and August 1, 2025, Li Yulan has already reduced her holdings by 5,000 shares, 15,000 shares, and 15,000 shares respectively, with average prices of 11.01 CNY/share, 12.18 CNY/share, and 13.68 CNY/share [1] - The total shares reduced so far amount to 35,000 shares, which represents 0.017% of total shares [1] - **Remaining Holdings** - After the reductions, Li Yulan holds 165,000 shares, which is 0.080% of total shares [1]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-060 湖南达嘉维康医药产业股份有限公司 关于高级管理人员减持计划时间届满暨减持计划实施完毕的公告 公司高级管理人员李玉兰保证向本公司提供的信息真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 2、本次减持计划已按照相关规定进行了预披露，实际减持股份数量未超过计划 减持股份数量，已披露的减持计划时间已届满。 3、截至本公告披露日，李玉兰女士严格遵守《首次公开发行股票并在创业板上 市招股说明书》和《首次公开发行股票并在创业板上市之上市公告书》中所做出的 相关承诺，未出现违反承诺的情形。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"或"达嘉维康"）于 2025 年 5 月 14 日披露了《关于董事、监事、高级管理人员减持股份的预披露公告》 （公告编号：2025-035），公司高级管理人员李玉兰计划在减持股份预披露公告之 日起 15 个交易日后的 3 个月内（即 2025 年 6 月 6 日至 2025 年 9 月 5 日）以集中竞 价交易方式减持本公司股份不超过 50, ...